ABSTRACT
Glycogenic hepatopathy (GH) is an uncommon cause of serum transaminase elevation in type I diabetes mellitus (DM). The clinical signs and symptoms of GH are nonspecific, and include abdominal discomfort, mild hepatomegaly, and transaminase elevation. In this report we describe three cases of patients presenting serum transaminase elevation and hepatomegaly with a history of poorly controlled type I DM. All of the cases showed sudden elevation of transaminase to more than 30 times the upper normal range (like in acute hepatitis) followed by sustained fluctuation (like in relapsing hepatitis). However, the patients did not show any symptom or sign of acute hepatitis. We therefore performed a liver biopsy to confirm the cause of liver enzyme elevation, which revealed GH. Clinicians should be aware of GH so as to prevent diagnostic delay and misdiagnosis, and have sufficient insight into GH; this will be aided by the present report of three cases along with a literature review.
-
Keywords: Glycogen hepatopathy; Transaminase; Type I diabetes mellitus
INTRODUCTION
Glycogenic hepatopathy (GH) was first identified at 1930 and it is characterized by elevated liver enzyme, hepatomegaly, and glycogen accumulation within hepatocytes and it can be found in patients with type I Diabetes Mellitus (DM) with poorly controlled blood sugar.
1,
2 Clinically, GH has been known to have benign nature; however it is difficult to distinguish with nonalcoholic fatty liver disease (NAFLD) which could progress into advance liver disease without histological confirmation.
2,
3 Recently, we have diagnosed three cases of GH presented marked serum transaminases elevation more than 30 times of upper normal range as like acute hepatitis with poorly controlled type I DM history. Since the first report, about 15 cases suspected as GH have been described in adults over the world. In Korea, before this report, only 2 cases of GH have been reported for adults, however, one case showed only mild AST elevation (65 U/L) and normal range of ALT and the other case showed mild liver enzyme elevation during diabetic ketoacidosis (DKA) management.
4,
5 On the contrary, our three cases of GH in this report showed dramatic elevation of liver enzyme as like acute hepatitis and sustained fluctuation as like relapsing hepatitis, and these findings are very rare and unique even among the all reports of GH over the world. So, we present these cases with literature review.
CASE REPORT
Case 1
A 22-year old female was referred to a hepatologist for evaluation of elevated liver enzymes. She had haven Type I DM for 8 years. When she visited our hospital one month ago, her liver function test had showed abnormal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) as 169 U/L (normal value <35) and 172 U/L (normal value <35), respectively. Four weeks later, at the time of the referral, her AST and ALT were elevated strikingly as 1028 U/L and 365 U/L. Other laboratory findings were total bilirubin (TB) 0.5 mg/dL (normal value <1.3), Alkaline phosphatase (ALP) 346 U/L (normal value <85), γ-glutamyl transpeptidase (γ-GT) 321 U/L (normal value <40), hemoglobin A1c (HbA1c) 13.8% (normal value <6), triglyceride(TG) 160 mg/dL, high-density lipoprotein (HDL) 114 mg/dL creatine kinase (CK) 127 UL (normal value <220). Auto-antibody including anti-nuclear antibody (ANA), smooth muscle antibodies (ASMA) and mitochondrial antibodies (AMA) were all negative. Thyroid function test and serum ceruloplasmin were also normal. The serologic findings for viral infection such as IgM anti-HAV, HBsAg, anti-HCV, HCV-RNA, cytomegalovirus and Epstein-Barr virus were also all negative. Her height, weight, body mass index (BMI) and waist circumference were 165.1 cm, 50.8 kg, 18.6 kg/m
2 and 72 cm respectively. Abdominal Ultrasonography (US) showed just a mild fatty change of liver and mild hepatomegaly (
Fig. 1). She was not an alcohol or drug consumer and was not taking any medication except insulin. In addition, she did not show any symptom and sign compatible with acute hepatitis. So, we recommend her for a liver biopsy to elucidate the cause of acute elevation of liver enzyme. In hematoxylin and eosin (H&E) stain, liver biopsy showed normal liver architecture with no evidence of hepatocellular injury, inflammation, fibrosis, or steatosis. However, the hepatocytes were diffusely swollen with pale cytoplasm. The periodic acid-Schiff (PAS) staining showed abundant glycogen accumulation within hepatocytes. So, histologically, it was diagnosed as a glycogenic hepatopathy (
Fig. 2). Eight weeks later, her transaminases were drooped suddenly without any special management. After this event, although we tried to control her sugar level strictly, her sugar control was still poor and HbA1c was maintained above 11% with mild fluctuation. Until now, her liver enzymes also have shown severe fluctuation continuously as like relapsing hepatitis (
Fig. 3A).
A 26-year year old female was referred to a hepatologist for evaluation of elevated liver enzymes. She had haven Type I DM for 9 years. Her glycemia had been poorly controlled with several episodes of DKA & DM gastropathy. When she visited our hospital 4 weeks ago, her AST and ALT had shown relatively mild elevation as 218 and 213 U/L, respectively. At the time of the referral, her AST and ALT were elevated strikingly to 914 U/L and 307U/L. Other laboratory findings were TB 0.5 mg/dL, ALP 189 U/L, γ-GT 294 U/L, HbA1c 12.9%, TG 185 mg/dL, HDL 112 mg/dL CK 112 UL. ANA, ASMA and AMA were all negative. Thyroid function test and serum ceruloplasmin were also normal. The serologic findings for viral infection were also all negative. Her height, weight, body mass index (BMI) and waist circumference were 154.3 cm, 56.3 kg, 23.6 kg/m
2 and 79 cm, respectively. Abdominal US showed just a mild fatty change of liver. She had no history of taking alcohol or drug except insulin. In addition, she did not show any symptom and sign compatible with acute hepatitis. In liver biopsy, histological findings were compatible with GH. Four weeks later, her transaminases dropped spontaneously without any special management. After this event, her glycemic control has been still poor and HbA1c has been maintained above 13%, liver enzyme levels have shown continuous fluctuation (
Fig. 3B).
A 20-year old female with type I DM during 10 years was referred to a hepatologist for elevated liver enzymes. When she visited our hospital 8weeks ago, her AST and ALT levels were within normal range as 13 and 9 U/L, respectively. At the time of the referral, her AST and ALT were elevated strikingly to 1,310 U/L and 346 U/L. Other laboratory finding such as TB (0.2 mg/dL), ALP (132 U/L), γ-GT (15 U/L), TG (112 mg/dL), HDL (36 mg/dL), CK 86 UL, thyroid function test, serum ceruloplasmin level were all normal. ANA, ASMA and AMA were also negative. The serologic findings for viral infection were also all negative. There was no history of taking alcohol or drug except insulin. Her glycemic control had been poor and HbA1c was 13.6%. Her height, weight, body mass index (BMI) and waist circumference were 149.8 cm, 47.1 kg and 21 kg/m
2, respectively. Abdominal US showed just a mild fatty change of liver. As former two cases, she did not show any symptom and sign compatible with acute hepatitis and GH was confirmed by liver biopsy. During the follow up, her glycemic control has been still poor and HbA1c has been maintained above 15%. However, her liver enzyme levels have shown dramatically down and maintenance within normal range (
Fig. 3C).
DISCUSSION
We reported three cases of GH which were associated with type I diabetes mellitus, causing a clinical picture of acute and relapsing hepatitis. GH can cause severe, but reversible elevations of serum transaminase levels in patients with poorly controlled type I diabetes due to hepatic glycogen accumulation. Long-standing hyperglycemia, over insulin use, glucose given to control hypoglycemia and increased concentrations of the counter regulatory hormones have been known as risk factors for hepatic glycogen accumulation in patients with type I DM by their actions on the glycogen phosphorylase and synthase enzymes.
6-
8
The typical clinical findings of GH are hepatomegaly and elevated liver enzymes, especially transaminases.
2,
3,
9-
14 However, there is no histological evidence that suggests the enzyme elevations are due to liver necrosis, so their elevation is considered as a result of hepatocyte's membrane injury to cause enzyme "leakage" instead of cell death. However, the exact mechanism as well as prevalence has not been well known. Liver biopsy is helpful to confirm the diagnosis of GH. Histological features in GH are characterized by large, swollen, glycogen-laden hepatocytes and glycogenated nuclei without significant fatty change, inflammation, lobular spotty necrosis or fibrosis.
1
The abnormality of transaminase in GH has been known to be easily treatable by improvement of glycemic control in a short time within 2 to 14 weeks.
4,
5,
12,
15 However, as seen in our case, the changes of liver enzyme levels showed somewhat different pattern compared with previous reported cases. The sudden elevation and dropping of transaminase did not showed any definitive correlation with the glycemic control (the change of HbA1C) and continuous fluctuation of transaminase as like relapsing hepatitis in case 1 and 2 is also unusual pattern compared to previous reports. In addition, there was no insulin dose-up even in acute flare-up phase of transaminase. So, it suggests that the changes of transaminases can be related with not only poor glycemic control or insulin therapy but also another factor which has not been clarified. In addition, in all cases, the AST dominant elevation compared to ALT is also impressive finding. Therefore, to elucidate the risk factors and more complete pathophysiology, more advanced systemic review and research have to be performed.
Clinically, to distinguish GH from NAFLD is important, because as mentioned above, the prognosis of both diseases are different. GH has been known to have benign nature whereas NAFLD could progress into advance liver disease such as cirrhosis or hepatocellular carcinoma.
2,
3 Including our cases, overall GH in diabetic patients with hepatomegaly and abnormal liver enzymes within 5-10 times of upper normal range have often been assumed to have NAFLD rather than GH in the initial diagnostic process. GH is a rare condition and many clinicians are unaware of it if no biopsy is obtained.
16 As mentioned above, especially in case of mild transaminases elevation in diabetic patients, liver biopsy is essential in differential diagnosis of GH with NAFLD. In addition, US finding is not helpful in distinguishing NAFLD from GH because both fatty liver and glycogen overload could show similar US finding as mild hyperechoic hepatic parenchyma.
3,
6,
10,
11 Consequently, the condition is often misdiagnosed and it result in wasting medical resources.
CONCLUSION
We encountered three cases of GH within only one year. It may suggest that many cases of GH have been missed due to a lack of interest by clinician. Clinician's awareness of GH should prevent diagnostic delay and misdiagnosis and will provide better insight and management for the GH.
FOOTNOTES
-
The authors have no conflicts to disclose.
Abbreviations
Anti-Mitochondrial Antibodies
antibody to hepatitis C virus
Anti-smooth muscle antibody
aspartate aminotransferase
hemoglobin A1c; HBsAg, hepatitis B surface antigen
hepatitis B surface antigen
Non-alcoholic fatty liver disease
REFERENCES
- 1. Mauriac P. Gros ventre, hepatomegalie, troubles de las croissance chez les enfants diabetiques traits depuis plusieurs annes par l'insuline. Gax Hebdo Med Bordeaux 1930;26:402-410.
- 2. Torbenson M, Chen YY, Brunt E, Cummings OW, Gottfried M, Jakate S, et al. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol 2006;30:508-513. 16625098.
- 3. Chatila R, West AB. Hepatomegaly and abnormal liver tests due to glycogenosis in adults with diabetes. Medicine (Baltimore) 1996;75:327-333. 8982149.
- 4. Park J, Song DH, Park JS, Nam JY, Kim CS, Kim DM, et al. A case of hepatomegaly due to diabetic glycogenosis reversed by glycemic control. J Korean Soc Endocrinol 2004;19:223-228.
- 5. Lee SH, Kwon HS, Shin JA, Kim WC, Kim JH, Choi YH, et al. A case of hepatic glycogenosis in a patient with uncontrolled type 1 diabetes mellitus. J Korean Diabetes Assoc 2006;30:82-86.
- 6. Munns CF, McCrossin RB, Thomsett MJ, Batch J. Hepatic glycogenosis: reversible hepatomegaly in type 1 diabetes. J Paediatr Child Health 2000;36:449-452. 11036799.
- 7. Tsujimoto T, Takano M, Nishiofuku M, Yoshiji H, Matsumura Y, Kuriyama S, et al. Rapid onset of glycogen storage hepatomegaly in a type-2 diabetic patient after a massive dose of long-acting insulin and large doses of glucose. Intern Med 2006;45:469-473. 16679704.
- 8. Petersen KF, Laurent D, Rothman DL, Cline GW, Shulman GI. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest 1998;101:1203-1209. 9502760.
- 9. Nakamuta M, Ohashi M, Goto K, Tanabe Y, Hiroshige K, Nawata H. Diabetes mellitus-associated glycogen storage hepatomegaly: report of a case and review of the Japanese literature. Fukuoka Igaku Zasshi 1993;84:354-358. 8359783.
- 10. Carcione L, Lombardo F, Messina MF, Rosano M, De Luca F. Liver glycogenosis as early manifestation in type 1 diabetes mellitus. Diabetes Nutr Metab 2003;16:182-184. 14635736.
- 11. Torres M, Lopez D. Liver glycogen storage associated with uncontrolled type 1 diabetes mellitus. J Hepatol 2001;35:538. 11682042.
- 12. Hudacko RM, Manoukian AV, Schneider SH, Fyfe B. Clinical resolution of glycogenic hepatopathy following improved glycemic control. J Diabetes Complications 2008;22:329-330. 18413180.
- 13. Bassett JT, Veerappan GR, Lee DH. Glycogenic hepatopathy: a rare cause of increased aminotransferase levels in a diabetic patient. Clin Gastroenterol Hepatol 2008;6:A26. 18691943.
- 14. Abaci A, Bekem O, Unuvar T, Ozer E, Bober E, Arslan N, et al. Hepatic glycogenosis: a rare cause of hepatomegaly in Type 1 diabetes mellitus. J Diabetes Complications 2008;22:325-328. 18413182.
- 15. Fridell JA, Saxena R, Chalasani NP, Goggins WC, Powelson JA, Cummings OW. Complete reversal of glycogen hepatopathy with pancreas transplantation: two cases. Transplantation 2007;83:84-86. 17220798.
- 16. Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol 2002;9:37-51. 11756758.
Figure 1Image findings. Abdominal ultrasonography showed mildly increased hepatic parenchymal echogenicity and mild hepatomegaly in case 1, which led to an initial suspicion of nonalcoholic fatty liver disease (A, B). The findings for cases 2 and 3 were similar.
Figure 2Histological findings for case 1. Hematoxylin and eosin staining showed a preserved portal and hepatic lobular architecture without significant inflammation, fibrosis, or cholestasis. The hepatocytes were diffusely swollen with a pale cytoplasm (arrowhead). Numerous hepatocytes exhibited glycogenated nuclei (×200) (A). Strong positivity for periodic acid-Schiff (PAS) stain (arrow) suggested cytoplasmic glycogen deposits (×200) (B). The findings for cases 2 and 3 were similar.
Figure 3Changes in serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and HbA1c in cases 1 (A), 2 (B), and 3 (C). In all cases the status of glycemic control did not show a definitive correlation with the changes in liver enzyme levels; the latter showed various fluctuations in each case.
Citations
Citations to this article as recorded by
- Transaminases in the Thousands: Glycogenic Hepatopathy Mimicking Acute Hepatitis
CP Ganesh, Naveen Bhagat, Dipanwita Biswas, Suvradeep Mitra, Shagun Singh, Arka De, Sunil Taneja, Ajay Duseja
Journal of Clinical and Experimental Hepatology.2026; 16(3): 103476. CrossRef - Improvement of Glycogenic Hepatopathy With Minimal Corresponding Improvement of Glycemic Control in a Person With Type 1 Diabetes: Case Report and Literature Review
Joselyn Tessa Tonleu, Nicolas A. Reyes, Natalie D. Hillerson, William B. Horton
AACE Clinical Case Reports.2025; 11(2): 113. CrossRef - Expanding the Differential Diagnosis: Severe, Swollen Hepatocytes in a Patient With ALT Above 1000 U/L
Michael Eller, Lindsey Westbrook, Avash Kalra
Gastroenterology.2025; 168(6): 1062. CrossRef - Hepatomegaly and Deranged Liver Enzymes in a Patient With Poorly Controlled Type 1 Diabetes Mellitus
George I Habeos, Dimitris Ziazias, Christina Petropoulou, Georgios Eleftherakis, Georgios K Markantes
JCEM Case Reports.2025;[Epub] CrossRef - Glycogenic Hepatopathy: A Case Report of a Rare Complication in Uncontrolled Diabetes
Mais Musleh, Amani AlMokbel
Clinical Case Reports.2025;[Epub] CrossRef - Glycogenic hepatopathy is associated with type 1 diabetes mellitus in only a minority of cases in a contemporary adult population
Brian K. Cox, Maha Guindi, Danielle Hutchings, Stacey A. Kim, Kevin M. Waters, Brent K. Larson
Annals of Diagnostic Pathology.2023; 64: 152130. CrossRef - A Case of Glycogenic Hepatopathy as a Complication of Poorly Controlled Type 1 Diabetes Mellitus
Samhitha Munugoti, Vamsee Reddy, Gaurav Patel, Maneesh Gaddam, Triveni Abburi, Osamu Isozaki
Case Reports in Endocrinology.2022; 2022: 1. CrossRef - Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy
Jonathan Mertens, Christophe De Block, Maarten Spinhoven, Ann Driessen, Sven M. Francque, Wilhelmus J. Kwanten
Frontiers in Pharmacology.2021;[Epub] CrossRef - Liver chemistries in glycogenic hepatopathy associated with type 1 diabetes mellitus: A systematic review and pooled analysis
Samir Haffar, Manhal Izzy, Hany Habib, Takaaki Sugihara, Darrick K. Li, Ayush Sharma, Zhen Wang, M. Hassan Murad, Kymberly D. Watt, Fateh Bazerbachi
Liver International.2021; 41(7): 1545. CrossRef - Glycogen Hepatopathy: A Reversible yet Relapsing Cause of Hepatitis in Type 1 Diabetics
Mishah Azhar, Muhammad Hammami, Ahmad Musmar, Matthew Bromer
Cureus.2021;[Epub] CrossRef - Glycogenic hepatopathy in children with poorly controlled type 1 diabetes mellitus
Nor Azizah Abu, Chooi Bee Lim, Noor Shafina Mohd Nor
Clinical Pediatric Endocrinology.2021; 30(2): 93. CrossRef - Hepatocellular Glycogen Accumulation in the Setting of Poorly Controlled Type 1 Diabetes Mellitus: Case Report and Review of the Literature
Atinuke Aluko, Ikponmwosa Enofe, Jacob Burch, Julie Yam, Nazia Khan
Case Reports in Hepatology.2020; 2020: 1. CrossRef - Glycogenic Hepatopathy: A Rare Hepatic Complication of Poorly Controlled Type 1 DM
Leila A. Alenazy, Muhammad Javed, Hussien Elsiesy, Emad Raddaoui, Waleed K. Al-Hamoudi
Case Reports in Medicine.2020; 2020: 1. CrossRef - Hepatomegaly and type 1 diabetes: a clinical case of Mauriac’s syndrome
Fortunato Lombardo, Stefano Passanisi, Albino Gasbarro, Giovanni Tuccari, Antonio Ieni, Giuseppina Salzano
Italian Journal of Pediatrics.2019;[Epub] CrossRef - Glycogenic hepatopathy as an unusual etiology of deranged liver function in a patient with type 1 diabetes
David TW Lui, Yu-Cho Woo, Wing-Sun Chow, Chi-Ho Lee, Alan CH Lee, Eunice KH Leung, Kathryn CB Tan, Karen SL Lam, Joanne KY Lam
Medicine.2019; 98(17): e15296. CrossRef - Mauriac syndrome: An unusual presentation with portal fibrosis
Mouna Medhioub, Hend Ayedi, Emna Chelbi, Amal Khsiba, Lamine Hamzaoui, Mohamed Moussadek Azzouz
La Presse Médicale.2019; 48(6): 718. CrossRef - Glycogenic Hepatopathy
Bashar Sharma, Marsha Antoine, Mili Shah, Rochelle Nagales Nagamos, Savio John
ACG Case Reports Journal.2019; 6(7): e00115. CrossRef - Glycogenic Hepatopathy in Type 1 Diabetes Mellitus
Shohei Asada, Hideto Kawaratani, Tsuyoshi Mashitani, Daisuke Kaya, Maiko Nishigori, Takuya Kubo, Yasuhiko Sawada, Yukihisa Fujinaga, Kosuke Kaji, Mitsuteru Kitade, Tadashi Namisaki, Kei Moriya, Akira Mitoro, Hitoshi Yoshiji
Internal Medicine.2018; 57(8): 1087. CrossRef - Focal Hepatic Glycogenosis in a Patient With Uncontrolled Diabetes Mellitus Type 1
Tetiana Glushko, Sergiy V. Kushchayev, Dmitry Trifanov, Aliaksei Salei, Diego Morales, Gerard Berry, Justin Mackey, Oleg M. Teytelboym
Journal of Computer Assisted Tomography.2018; 42(2): 230. CrossRef - Glycogenic hepatopathy
Johad Khoury, Yaniv Zohar, Naim Shehadeh, Tarek Saadi
Hepatobiliary & Pancreatic Diseases International.2018; 17(2): 113. CrossRef - Glycogenic hepatopathy: A narrative review
Jagannath M Sherigar, Joline De Castro, Yong Mei Yin, Debra Guss, Smruti R Mohanty
World Journal of Hepatology.2018; 10(2): 172. CrossRef - Glycogen Hepatopathy: A Rare and Underrecognized Cause of Recurrent Transaminitis in Patients with Uncontrolled Type 2 Diabetes Mellitus
Kishore Kumar, Shehriyar Mehershahi, Chukwunonso Chime, Hassan Tariq, Suresh Kumar Nayudu, Sridhar Chilimuri
Case Reports in Gastroenterology.2018; 12(2): 466. CrossRef - Four cases of type 1 diabetes mellitus showing sharp serum transaminase increases and hepatomegaly due to glycogenic hepatopathy
Yuichi Ikarashi, Tomomi Kogiso, Etsuko Hashimoto, Kuniko Yamamoto, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii, Hiroko Takaike, Yasuko Uchigata, Katsutoshi Tokushige
Hepatology Research.2017;[Epub] CrossRef - Glycogenic Hepatopathy: Resolution with Minimal Glucose Control
Abhimanyu Chandel, Brittany Scarpato, Jeanette Camacho, Miles McFarland, Shaffer Mok
Case Reports in Hepatology.2017; 2017: 1. CrossRef - Glycogenic hepatopathy in young adults: a case series
Marco Silva, Margarida Marques, Hélder Cardoso, Susana Rodrigues, Patrícia Andrade, Armando Peixoto, Joana Pardal, Joanne Lopes, Fátima Carneiro, Guilherme Macedo
Revista Española de Enfermedades Digestivas.2016;[Epub] CrossRef - Glycogenic Hepatopathy: Thinking Outside the Box
Nishant Parmar, Muslim Atiq, Lee Austin, Ross A. Miller, Thomas Smyrk, Kabir Ahmed
Case Reports in Gastroenterology.2015; 9(2): 221. CrossRef - Glycogenic hepatopathy in a Korean girl with poorly controlled type 1 diabetes mellitus
Hwal Rim Jeong, Young Seok Shim, Young Bae Kim, Hae Sang Lee, Jin Soon Hwang
Annals of Pediatric Endocrinology & Metabolism.2014; 19(1): 49. CrossRef
